Papapetrou Eirini P, Kovalovsky Damian, Beloeil Laurent, Sant'angelo Derek, Sadelain Michel
Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
J Clin Invest. 2009 Jan;119(1):157-68. doi: 10.1172/JCI37216. Epub 2008 Dec 1.
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression by targeting complementary sequences, referred to as miRNA recognition elements (MREs), typically located in the 3' untranslated region of mRNAs. miR-181a is highly expressed in developing thymocytes and markedly downregulated in post-thymic T cells. We investigated whether endogenous miR-181a can be harnessed to segregate expression of chimeric antigen receptors (CARs) and TCRs between developing and mature T cells. Lentiviral-encoded antigen receptors were tagged with a miR-181a-specific MRE and transduced into mouse BM cells that were used to generate hematopoietic chimeras. Expression of a CAR specific for human CD19 (hCD19) was selectively suppressed in late double-negative and double-positive thymocytes, coinciding with the peak in endogenous miR-181a expression. Receptor expression was fully restored in post-thymic resting and activated T cells, affording protection against a subsequent challenge with hCD19+ tumors. Hematopoietic mouse chimeras engrafted with a conalbumin-specific TCR prone to thymic clonal deletion acquired peptide-specific T cell responsiveness only when the vector-encoded TCR transcript was similarly engineered to be subject to regulation by miR-181a. These results demonstrate the potential of miRNA-regulated transgene expression in stem cell-based therapies, including cancer immunotherapy.
微小RNA(miRNA)是一类小的非编码RNA,通过靶向通常位于mRNA 3'非翻译区的互补序列(称为miRNA识别元件,即MRE)来调节基因表达。miR-181a在发育中的胸腺细胞中高度表达,而在胸腺后的T细胞中显著下调。我们研究了内源性miR-181a是否可用于在发育中的T细胞和成熟T细胞之间分离嵌合抗原受体(CAR)和T细胞受体(TCR)的表达。慢病毒编码的抗原受体用miR-181a特异性MRE进行标记,并转导到小鼠骨髓细胞中,用于生成造血嵌合体。对人CD19(hCD19)具有特异性的CAR表达在晚期双阴性和双阳性胸腺细胞中被选择性抑制,这与内源性miR-181a表达的峰值一致。在胸腺后的静息和活化T细胞中,受体表达完全恢复,从而提供针对随后hCD19+肿瘤攻击的保护。移植了易发生胸腺克隆缺失的伴清蛋白特异性TCR的造血小鼠嵌合体,只有当载体编码的TCR转录本经过类似设计使其受miR-181a调控时,才获得肽特异性T细胞反应性。这些结果证明了miRNA调节的转基因表达在基于干细胞的治疗(包括癌症免疫治疗)中的潜力。